Format
Sort by
Items per page

Send to

Choose Destination

Best matches for GLATIRAMER/TU:

Demonstration of equivalence of a generic glatiramer acetate (Glatopa™). Anderson J et al. J Neurol Sci. (2015)

Two decades of glatiramer acetate: From initial discovery to the current development of generics. Weinstock-Guttman B et al. J Neurol Sci. (2017)

Glatiramer acetate during early pregnancy: A prospective cohort study. Herbstritt S et al. Mult Scler. (2016)

Search results

Items: 1 to 20 of 182

1.

The Novel Effect of Immunomodulator-Glatiramer Acetate on Epileptogenesis and Epileptic Seizures.

Lai MC, Lin KM, Yeh PS, Wu SN, Huang CW.

Cell Physiol Biochem. 2018;50(1):150-168. doi: 10.1159/000493965. Epub 2018 Oct 2.

2.

A case of oligodendroglioma and multiple sclerosis: Occam's razor or Hickam's dictum?

Shirani A, Wu GF, Giannini C, Cross AH.

BMJ Case Rep. 2018 Jun 28;2018. pii: bcr-2018-225318. doi: 10.1136/bcr-2018-225318.

PMID:
29954769
3.

[Effect of preventive treatment on cognitive performance in patients with multiple sclerosis].

Shorobura MS.

Wiad Lek. 2018;71(3 pt 2):648-652. Ukrainian.

PMID:
29783240
4.

Corpus callosum demyelination associated with acquired stuttering.

Decker BM, Guitar B, Solomon A.

BMJ Case Rep. 2018 Apr 21;2018. pii: bcr-2017-223486. doi: 10.1136/bcr-2017-223486.

PMID:
29680798
5.

Serum anti-JCV antibody indexes in Japanese patients with multiple sclerosis: elevations along with fingolimod treatment duration.

Aoyama S, Mori M, Uzawa A, Uchida T, Masuda H, Ohtani R, Kuwabara S.

J Neurol. 2018 May;265(5):1145-1150. doi: 10.1007/s00415-018-8813-z. Epub 2018 Mar 12.

PMID:
29532286
6.

Managing the side effects of multiple sclerosis therapy: pharmacotherapy options for patients.

Rommer PS, Zettl UK.

Expert Opin Pharmacother. 2018 Apr;19(5):483-498. doi: 10.1080/14656566.2018.1446944. Epub 2018 Mar 12. Review.

PMID:
29528247
7.

Immunoregulation of Theiler's virus-induced demyelinating disease by glatiramer acetate without suppression of antiviral immune responses.

Omura S, Sato F, Martinez NE, Range T, Ekshyyan L, Minagar A, Alexander JS, Tsunoda I.

Arch Virol. 2018 May;163(5):1279-1284. doi: 10.1007/s00705-018-3729-6. Epub 2018 Jan 23.

8.

Short- and long-term clinical outcomes of use of beta-interferon or glatiramer acetate for people with clinically isolated syndrome: a systematic review of randomised controlled trials and network meta-analysis.

Armoiry X, Kan A, Melendez-Torres GJ, Court R, Sutcliffe P, Auguste P, Madan J, Counsell C, Clarke A.

J Neurol. 2018 May;265(5):999-1009. doi: 10.1007/s00415-018-8752-8. Epub 2018 Jan 22. Review.

9.

Effects of multiple sclerosis and medications on menopausal age.

Türk Börü Ü, Köseoğlu Toksoy C, Bölük C, Bilgiç A, Taşdemir M.

J Int Med Res. 2018 Mar;46(3):1249-1253. doi: 10.1177/0300060517746026. Epub 2018 Jan 14.

10.

Multiple Sclerosis.

Reich DS, Lucchinetti CF, Calabresi PA.

N Engl J Med. 2018 Jan 11;378(2):169-180. doi: 10.1056/NEJMra1401483. Review. No abstract available.

PMID:
29320652
11.

Featured Article: Modulation of the OGF-OGFr pathway alters cytokine profiles in experimental autoimmune encephalomyelitis and multiple sclerosis.

Ludwig MD, Zagon IS, McLaughlin PJ.

Exp Biol Med (Maywood). 2018 Feb;243(4):361-369. doi: 10.1177/1535370217749830. Epub 2018 Jan 7.

PMID:
29307283
12.

[Efficacy, safety and tolerability of glatiramer acetate injections in dose 40 mg/ml in patients with relapsing-remitting multiple sclerosis].

Boyko AN, Alifirova VM.

Zh Nevrol Psikhiatr Im S S Korsakova. 2017;117(11):135-139. doi: 10.17116/jnevro2017117111135-139. Review. Russian.

PMID:
29265099
13.

Multiple sclerosis, a treatable disease .

Doshi A, Chataway J.

Clin Med (Lond). 2017 Dec;17(6):530-536. doi: 10.7861/clinmedicine.17-6-530. Review.

PMID:
29196354
14.

Long-term follow-up of a randomized study of combination interferon and glatiramer acetate in multiple sclerosis: Efficacy and safety results up to 7 years.

Lublin FD, Cofield SS, Cutter GR, Gustafson T, Krieger S, Narayana PA, Nelson F, Salter AR, Wolinsky JS.

Mult Scler Relat Disord. 2017 Nov;18:95-102. doi: 10.1016/j.msard.2017.09.012. Epub 2017 Sep 23.

15.

The complement system as a biomarker of disease activity and response to treatment in multiple sclerosis.

Tatomir A, Talpos-Caia A, Anselmo F, Kruszewski AM, Boodhoo D, Rus V, Rus H.

Immunol Res. 2017 Dec;65(6):1103-1109. doi: 10.1007/s12026-017-8961-8. Review.

PMID:
29116612
16.

Pharmacogenetics of glatiramer acetate therapy for multiple sclerosis: the impact of genome-wide association studies identified disease risk loci.

Kulakova O, Bashinskaya V, Kiselev I, Baulina N, Tsareva E, Nikolaev R, Kozin M, Shchur S, Favorov A, Boyko A, Favorova O.

Pharmacogenomics. 2017 Nov;18(17):1563-1574. doi: 10.2217/pgs-2017-0058. Epub 2017 Nov 2.

PMID:
29095108
17.

Decreased serum levels of sCD40L and IL-31 correlate in treated patients with Relapsing-Remitting Multiple Sclerosis.

de J Guerrero-García J, Rojas-Mayorquín AE, Valle Y, Padilla-Gutiérrez JR, Castañeda-Moreno VA, Mireles-Ramírez MA, Muñoz-Valle JF, Ortuño-Sahagún D.

Immunobiology. 2018 Jan;223(1):135-141. doi: 10.1016/j.imbio.2017.10.001. Epub 2017 Oct 5.

PMID:
29050818
18.

Clinical effectiveness and cost-effectiveness of beta-interferon and glatiramer acetate for treating multiple sclerosis: systematic review and economic evaluation.

Melendez-Torres GJ, Auguste P, Armoiry X, Maheswaran H, Court R, Madan J, Kan A, Lin S, Counsell C, Patterson J, Rodrigues J, Ciccarelli O, Fraser H, Clarke A.

Health Technol Assess. 2017 Sep;21(52):1-352. doi: 10.3310/hta21520. Review.

19.

Adherence, persistence, and discontinuation among Hispanic and African American patients with multiple sclerosis treated with fingolimod or glatiramer acetate.

Williams MJ, Johnson K, Trenz HM, Korrer S, Halpern R, Park Y, Herrera V.

Curr Med Res Opin. 2018 Jan;34(1):107-115. doi: 10.1080/03007995.2017.1374937. Epub 2017 Oct 3.

PMID:
28857632
20.

Genomic correlates of glatiramer acetate adverse cardiovascular effects lead to a novel locus mediating coronary risk.

Brænne I, Zeng L, Willenborg C, Tragante V, Kessler T; CARDIoGRAM Consortium; CARDIoGRAMplusC4D Consortium, Willer CJ, Laakso M, Wallentin L, Franks PW, Salomaa V, Dehghan A, Meitinger T, Samani NJ, Asselbergs FW, Erdmann J, Schunkert H.

PLoS One. 2017 Aug 22;12(8):e0182999. doi: 10.1371/journal.pone.0182999. eCollection 2017.

Supplemental Content

Loading ...
Support Center